Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Spry

ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anaphylaxis. Co-founder

MarketBeat · May 15

ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) filed a petition Monday urging the FDA to delay approval of Aquestive Therapeutics Inc.'s (NASDAQ:AQST) experimental epinephrine treatment, citing safety, dosing, and real-world use concerns.

Benzinga · Sep 23, 2025

‘More tram-spotting than Trainspotting’: the new tram linking Leith to Edinburgh

The tramline to the old port means its Michelin-starred restaurants, seafront and cool venues are now just a few stops away from Edinburgh city centre

The Guardian - UK · Jun 6, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Community college athletes could earn $48 per Instagram post under the right conditions

When people talk about how college athletes can now get paid from their name, image and likeness – more commonly referred to as “NIL” – the focus is often on players at schools with big-time sports programs.

The Conversation · Sep 7, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.